The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 462.50
Bid: 455.00
Ask: 470.00
Change: 0.00 (0.00%)
Spread: 15.00 (3.297%)
Open: 462.50
High: 462.50
Low: 462.50
Prev. Close: 462.50
TSTL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New infection control range for dental practices

9 Mar 2009 07:00

RNS Number : 4908O
Tristel PLC
09 March 2009
 



 

TRISTEL plc ("Tristel" or the "Company"

AIM: TSTL

New infection control range for dental practices

Tristel plc, a leading provider of infection control products into the NHS and private health sector, announces the launch of its new Dentel range, the new infection control range for dental practices.

Using the Company's unique patented chlorine dioxide chemistry, Dentel products are sporicidal and rapidly effective against all micro-organisms. Tristel's Dentel range offers NHS and private dental practices a complete infection control response to the risks encountered in all types of dental procedures. Dentel 5, Dentel 100 and Dentel Duo are sporicidal solutions and foams designed for use on dental chair water bottles, saliva ejectors, suction systems, dental chairs and instrument tables.

Tristel have appointed the Dental Buying Group, the provider of high quality products and services to the dental profession of the United Kingdom, to introduce the Dentel range into dental surgeries. The Dental Buying Group was founded to look after the buying needs of the dental practice of which there are 7,000 members who benefit from services and products aimed at saving time and money.

Tristel is already well established in the hospital setting and the launch of the new Dentel range demonstrates the potential to move into other sectors.

http://www.tristel.com/dental.html

Contacts:

Tristel plc

Tel: 01638 721 500

Paul Swinney, Chief Executive

Daniel Stewart & Company Plc

Tel: 020 7776 6550

Graham Webster

Parkgreen Communications Ltd

Tel: 020 7933 8790

Helen Westaway

Mob: 07841 917 679

helen.westaway@parkgreenmedia.com

About Tristel

Tristel uses proprietary chlorine dioxide chemistry to create instrument and surface disinfectants. With its origins as a healthcare business specialising in infection control products, Tristel has recently extended its operations to include legionella control in water supplies and contamination control in the food and pharmaceutical industries. 

The company is creating applications for its chemistry that address the four routes of transmission of infection and contamination - surfaces, instruments, water and people.

Tristel plc has its headquarters in NewmarketUK and a network of distributors around the world. The company was admitted to trading on AIM on 1 June 2005. Its stock exchange symbol is TSTL.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAEAKDKESDNEFE
Date   Source Headline
16th Apr 20242:04 pmRNSDirector/PDMR Shareholding
15th Apr 20245:56 pmRNSExercise of Share Options and Total Voting Rights
19th Mar 20249:25 amRNSExercise of Share Options and Total Voting Rights
27th Feb 20247:00 amRNSExercise of Share Options and Total Voting Rights
26th Feb 20247:01 amRNSHalf-year Report
26th Feb 20247:00 amRNSUK and EU regulatory approval update
8th Feb 20247:00 amRNSExercise of Share Options and Total Voting Rights
1st Feb 20247:00 amRNSNotice of Interim Results
25th Jan 20247:00 amRNSExercise of Share Options and Total Voting Rights
23rd Jan 20247:00 amRNSCanadian regulatory approval for Tristel ULT
10th Jan 20242:27 pmRNSDirector/PDMR Shareholding
19th Dec 202312:02 pmRNSResult of AGM
19th Dec 20237:00 amRNSAGM Statement
7th Dec 20232:05 pmRNSExercise of Share Options and Total Voting Rights
1st Dec 20237:00 amRNSExercise of Share Options and Total Voting Rights
29th Nov 202312:40 pmRNSExercise of Share Options and Total Voting Rights
7th Nov 202311:00 amRNSExercise of Share Options and Total Voting Rights
16th Oct 20237:00 amRNSAudited Preliminary Results
12th Oct 20237:00 amRNSAdditional Investor Presentation
10th Oct 20234:45 pmRNSExercise of Share Options and Total Voting Rights
2nd Oct 202311:50 amRNSHolding(s) in Company
28th Sep 20232:00 pmRNSExercise of Share Options and Total Voting Rights
26th Sep 20232:40 pmRNSHolding(s) in Company
25th Sep 20238:40 amRNSHolding(s) in Company
22nd Sep 20233:40 pmRNSHolding(s) in Company
12th Sep 20237:00 amRNSNotice of Results
4th Sep 20237:00 amRNSHealth Canada regulatory approval submission
31st Jul 20238:05 amRNSHolding(s) in Company
28th Jul 20238:28 amRNSDirector/PDMR Shareholding
25th Jul 20237:00 amRNSTrading update
12th Jul 20237:00 amRNSShareholder Open Day and Notice of Trading Update
10th Jul 20237:00 amRNSExercise of Share Options and Total Voting Rights
26th Jun 20237:00 amRNSDirector/PDMR Shareholding
22nd Jun 20234:01 pmRNSHolding(s) in Company
16th Jun 20237:00 amRNSExercise of Share Options and Total Voting Rights
14th Jun 20234:10 pmRNSHolding(s) in Company
6th Jun 20235:00 pmRNSExercise of Share Options and Total Voting Rights
5th Jun 202310:00 amRNSAnalyst and Investor presentation
5th Jun 20237:00 amRNSFDA De Novo approval
28th Mar 202311:30 amRNSIssue of Equity
27th Mar 20237:00 amRNSSuccessful submission of additional data to US FDA
14th Mar 20232:05 pmRNSSecond Price Monitoring Extn
14th Mar 20232:00 pmRNSPrice Monitoring Extension
14th Mar 20239:30 amRNSIssue of Equity
22nd Feb 20234:30 pmRNSIssue of Equity
20th Feb 20237:00 amRNSHalf-year Report
30th Jan 20237:00 amRNSNotice of Results and Investor presentation
14th Dec 202211:00 amRNSResult of AGM - Replacement
13th Dec 20227:00 amRNSIssue of Equity
12th Dec 202211:26 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.